The venous thrombotic risk in nonsurgical patients

Drugs

Volumn 52, Issue SUPPL. 7, 1996, Pages 16-29

  Bouthier, Jean ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

CLINICAL TRIAL; CONFERENCE PAPER; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; INTENSIVE CARE; LUNG EMBOLISM; RISK; RISK BENEFIT ANALYSIS; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0030478360     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600527-00005     Document Type: Conference Paper

References (42)

1. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-facility rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151: 933-8
2. Hull RD, Feldstein W, Pineo G, et al. Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost 1995; 74 (I): 189-96
3. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J Royal Soc Med 1989; 82: 198-200
4. Donaldson GA, Williams C, Scannell JG, et al. A reappraisal of the application of the Trendelenburg operation to massive fatal PE: report of a successful pulmonary-artery thrombectomy using a cardiopulmonary bypass. N Engl J Med 1963; 268: 171-4
5. Anderson FA, Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg 1992; 16: 707-14
6. Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism - the Framingham study. JAMA 1983; 74: 1023-8
7. Anderson FA, Wheeler HB, Goldberg R, et al. Physician practices in the prevention of venous thromboembolism. Ann Int Med 1991; 115: 591-5
8. Handley AJ, Emerson PA, Fleming PR. Heparin in the prevention of deep vein thrombosis after myocardial infarction. BMJ 1972; 2: 436-8
9. Handley AJ. Low dose heparin after myocardial infarction. Lancet 1972; 1: 623-4
10. Warlow C, Terry G, Kenmure ACF, et al. A double blind trial of low doses of subcutaneous heparin in the prevention of deep vein thrombosis after myocardial infarction. Lancet 1973; October 27: 934-6
11. Emerson PA, Marks P. Preventing thromboembolism after myocardial infarction: effect of low dose heparin or smoking. BMJ 1977; 1: 18-20
12. Pitt A, Anderson ST, Habersberger P, et al. Low dose heparin in the prevention of deep-vein thromboses in patients with acute myocardial infarction. Am Heart J 1980; 99 (5): 574-8
13. Maurer BJ, Wray R, Shillingford JP. Frequency of venous thrombosis following myocardial infarction. Lancet 1971; 2: 1385
14. Miller RR, Lies JE, Caretta RF, et al. Prevention of lower extremity venous thrombosis by early mobilisation. Ann Intern Med 1976; 84: 700
15. 125I-fibrinogen test after acute myocardial infarction. Ann Clin Res 1973; 5: 365
16. Cristal N, Stern J, Ronen M, et al. Identifying patients at risk for thromboembolism. JAMA 1976; 236: 2755
17. Kakkar VV, Flanc C, Howe CT, et al. Natural history of postoperative vein thrombosis. Lancet 1969; 2: 230
18. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected DVT: a randomized trial. Ann Intern Med 1985; 21: 102
19. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989; 320: 352-7
20. ISIS-3 Collaborative group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs apirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-81
21. McCarthy ST, Tyrner J. Low dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 1986; 15: 84-8
22. McCarthy ST, Robertson D, Turner JJ, et al. Low dose heparin as a prophylaxis against deep vein thrombosis after acute stroke. Lancet 1977; 2: 800-1
23. Czechanowski B, Heinrich F. Prophylaxe venoser Thrombosen bei frischen ischamischen zerebrovaskularem Insult Doppelblindstudie mit Heprin Dihydroergot. Dtsch Med Wochenschr 1981; 106: 1254-60
24. Duke RJ, Turpie AG, Bloch RF, et al. Clinical trial of low-dose subcutaneous heparin for the prevention of stroke: natural history of acute partial stroke and stroke-in-evolution. In: Reivich M, Hurtig HI, editors. Cerebrovascular disease. New York: Raven Press, 1983: 399-405
25. Turpie AGG, Hirsh J, Jay RM, et al. Double blind randomised trial of ORG 10172 low molecular weight heparinoid in prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987; 8532: 523-6
26. Prins MH, Geselma R, Sing AK, et al. Prophylaxis of deep vein thrombosis with a low molecular weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis 1989; 19: 245-50
27. Elias A, Milandre L, Lagrange G, et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Rev Med Intern 1990; 11: 95-8
28. Scmidt EV, Smirnov VE, Ryabova VS. Results of the seven-year prospective study of stroke patients. Stroke 1988; 19: 942-9
29. Clagett GP, Anderson Jr FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995; 108/4: 312S-34S
30. Sandercock PAG, van den Belt AGM, Lindley RI, et al. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993; 56: 17-25
31. Kay R, Sing Wong K, Ling Yu Y, et al. Low molecular weight heparin for the treatment of acute stroke. N Engl J Med 1995; 333: 1588-93
32. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10 (7): 448-50
33. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995; 274: 335-7
34. Wells PS, Lensing AWA, Davidson B, et al. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. Ann Intern Med 1995; 122: 47-53
35. Arcellus JI, Candocia S, Traverso C, et al. Venous thomboembolism prophylaxis and risk assessment in medical patients. Sem Thromb Hemost 1991; 17 (3): 313-8
36. Belch JJ, Lowe GDO, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26. 115-7
37. Gärdlung B, for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996; 347: 1357-61
38. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5
39. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double blind trial. Haemostasis 1986; 16: 159-64
40. Lechler E, Schramm W, Flosbach CW, et al. The venous thrombotic risk in nonsurgical patients: epidemiological data and efficacy/safely profile of a low molecular weight heparin (enoxaparin). Haemostasis 1996; 26 Suppl. 2: 49-56
41. Harenberg J, Roebruck P, Heinrich F, et al. A randomised double blind trial of low molecular weight heparin for prophylaxis of venous thromboembolism in medical in-patients [abstract 380]. Thromb Haemost 1993; 69: 48
42. Bergmann JF, Elkharrat D. Prevention of venous thrombotic risk in non surgical patients. Haemostasis 1996; 26 Suppl. 2: 16-23